The Role of Medical Literature, Clinical Trials and Experimental Research in Drug Product-Injury Litigation: A Primer with Two Examples — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
The Role of Medical Literature, Clinical Trials and Experimental Research in Drug Product-Injury Litigation: A Primer with Two Examples
Kitzen Pharmaceutical Consulting, Collegeville, USA
,
Temple University School of Medicine, Philadelphia, USA
,
NEMA Research, Inc., Naples, USA
,
NEMA Research, Inc., Naples, USA
,
University of Arizona College of Pharmacy, Tucson, USA
,
Temple University School of Pharmacy, Philadelphia,USA
1 Kitzen Pharmaceutical Consulting, Collegeville, USA
2 Temple University School of Medicine, Philadelphia, USA
3 NEMA Research, Inc., Naples, USA
4 NEMA Research, Inc., Naples, USA
5 University of Arizona College of Pharmacy, Tucson, USA
6 Temple University School of Pharmacy, Philadelphia,USA
When any type of product has been ordered to be removed from the marketplace by a governmental regulatory body, that action is a powerful indicator that the product has been determined to be unsafe for further use, thereby branding the product as defective and opening up the possibility of product liability litigation. When the product is a drug or medical device, it is especially serious since the possibility of personal injury (acute and/or chronic) or death may occur. Needless to say, in these situations, product injury litigation will almost surely follow. We review the definition and requisite claims needed to establish drug product liability, and the role that the medical literature, clinical trial data, and even experimental research data can play in product (drug)-injury litigation. We show how each of these resources played a significant role in two well-known cases: Fen-Phen and thimerosal. The ultimate goal of such knowledge is to make better informed decisions about drug safety.
Lamb, T. (2018) Drug Injury Watch. http://www.drug-injury.com/
FDA (2018) Reports Received and Reports Entered into FAERS by Year. https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070434.htm
Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993) U.S. Supreme Court, 509 U.S. 579, No. 92-102.
Kumho Tire Company, Ltd. v. Carmichael. (1999) U.S. Supreme Court, 131 f.3d 1433, No. 97-1709.
Reference for Business (2018) Product Liability. http://www.referenceforbusiness.com/small/Op-Qu/Product-Liability.html
James, P., Oparil, S., Carter, BL., et al. (2014) Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). Journal of the American Medical Association, 311, 507-520. https://doi.org/10.1001/jama.2013.284427
Ascione, F.J. (2001) Principles of Scientific Literature Evaluation: Critiquing Clinical Trials. American Pharmaceutical Association, Washington DC.
Connolly, H.M., Crary, J.L., McGoon, M.D., et al. (1997) Valvular Heart Disease Associated with Fenfluramine-Phentermine. The New England Journal of Medicine, 337, 581-588.
Gardin, J.M., Weissman, N.J., Leung, C., et al. (2001) Clinical and Echocardiographic Follow-Up of Patients Previously Treated with Dexfenfluramine or Phentermine/Fenfluramine. Journal of the American Medical Association, 286, 2011-2014.
Steffee, C.H., Singh, H.K. and Chitwood, W.R. (1999) Histologic Changes in Three Explanted Native Cardiac Valves Following Use of Fenfluramines. Cardiovascular Pathology, 8, 245-253. https://doi.org/10.1016/S1054-8807(99)00019-8
Rothman, R.B., Baumann, M.H., Savage, J.E., et al. (2000) Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated with Fenfluramine and Other Serotonergic Medications. Circulation, 102, 2836-2841. https://doi.org/10.1161/01.CIR.102.23.2836
Sackett, D.L., Straus, S.E., Richardson, W.S., Rosenberg, W. and Haynes, R.B. (2000) Evidence-Based Medicine: How to Practice and Teach EBM. 2nd Edition, Churchill Livingstone, Edinburgh.
Schechter, R. and Grether, J.K. (2008) Continuing Increases in Autism Reported to California’s Developmental Services System. Archives of General Psychiatry, 65, 19-24.
Institute of Medicine (2004) Immunization Safety Review: Vaccines and Autism. National Academies Press, Washington DC.
Bernard, S., Enayati, A., Redwood, L., Roger, H. and Binstock, T. (2001) Autism: A Novel Form of Mercury Poisoning. Medical Hypotheses, 56, 462-471.
Bernard, S., Enayati, A., Roger, H., Binstock, T. and Redwood, L. (2002) The Role of Mercury in the Pathogenesis of Autism. Molecular Psychiatry, 7, S42-S43. https://doi.org/10.1038/sj.mp.4001177
Suzuki, T., Miyama, T. and Katsunuma, H. (1963) Comparative Study of Bodily Distribution of Mercury in Mice after Subcutaneous Administration of Methyl, Ethyl and N-Propyl Mercury Acetates. Japanese Journal of Experimental Medicine, 33, 277-282.
Centers for Disease Control and Prevention (1999) Thimerosal in Vaccines: A Joint Statement of the American Academy of Pediatrics and the Public Health Service. MMWR. Morbidity and Mortality Weekly Report, 48, 563-565. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4826a3.htm
Kanner, L. (1943) Autistic Disturbances of Affective Contact. Nervous Child, 2, 217-250.
Wing, L. and Potter, D. (2002) The Epidemiology of Autistic Spectrum Disorders: Is the Prevalence Rising? Mental Retardation and Developmental Disabilities Research Reviews, 8, 151-161.
Wakefield, A.J., Murch, S.H., Linnell, A.A.J., et al. (1998) Ileal-Lymphoid-Nodular Hyperplasia, Non-Specific Colitis and Pervasive Developmental Disorder in Children. The Lancet, 351, 637-641. https://doi.org/10.1016/S0140-6736(97)11096-0
CDC (2018) Data and Statistics. https://www.cdc.gov/ncbddd/autism/data.html
Madsen, K.M., Lauritsen, M.B., Pedersen, C.B., et al. Thimerosal and the Occurrence of Autism: Negative Ecological Evidence from Danish Population-Based Data. Pediatrics, 112, 604-606. https://doi.org/10.1542/peds.112.3.604
Bakir, F., Damluji, S.F., Amin-Zaki, L., et al. (1973) Methylmercury Poisoning in Iraq. Science, 181, 230-241. https://doi.org/10.1126/science.181.4096.230
Kurland, L.Y., Faro, S.N. and Siedler, H. (1960) Minamata Disease: The Outbreak of a Neurologic Disorder in Minamata, Japan, and Its Relationship to the Ingestion of Seafood Contaminated by Mercurial Compounds. World Neurology, 1, 370-375.
Institute of Medicine (2001) Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. National Academy Press, Washington DC.
Pichichero, M.E., Cernichiari, E., Lopreiato, J. and Treanor, J. (2002) Mercury Concentrations and Metabolism in Infants Receiving Vaccines Containing Thiomersal: A Descriptive Study. The Lancet, 360, 1737-1741. https://doi.org/10.1016/S0140-6736(02)11682-5
Nose, K. (1969) Studies on the Toxicity of Low Alkyl Mercury Compounds. Japanese Journal of Hygiene, 24, 359-367. https://doi.org/10.1265/jjh.24.359
Suzuki, K., Nakajima, K., Otaki, N. and Kimura, M. (1994) Metallothionein in Developing Human Brain. Neurosignals, 3, 188-192. https://doi.org/10.1159/000109544
Monks, T.J., Ghersi-Egea, J.F., Philbert, M., Cooper, A.J. and Lock, E.A. (1999) Symposium Overview: The Role of Glutathione in Neuroprotection and Neurotoxicity. Toxicological Sciences, 51, 161-177. https://doi.org/10.1093/toxsci/51.2.161
Blackwell et al. v. Sigma Aldrich, Inc. (2008) Thimerosal-Autism Link Rejected by Maryland Court. Wyeth Press Release 14 January.